Lovo works for
any manufacturing process.
test-field-label-DEFAULTVALUE-2
Lovo can automate preparation for magnetic selections, simplifying and expediting day 0 processing. With Lovo 3.0 software, you have the option to incorporate mid-procedure, timed incubations in your protocol design.
| Measure | Result | |
|---|---|---|
| Source Products | Collections | n=5 |
| Volume | 163.3 ± 28.5 mL | |
| Total Nucleated Cells (TNC) | 10.9 ± 3.4 x 109 | |
| Platelet Count | 4.46 ± 0.92 x 10 11 | |
| Processing Time | Automated Processing Time (With incubation) | 58 minutes |
| Max Processing Time | 61 minutes | |
Source: Data on file 223-REP-048957
| Measure | Result | |
|---|---|---|
| 2 wash cycles to remove platelets and prepare for incubation | Platelet Depletion | 98.4 ± 1.0% |
| Targeted Pre-Incubation Volume | 100 mL | |
| Actual Pre-Incubation Volume | 100.6 ± 1.2 mL | |
| Full Procedure | TNC recovery | 97.2 ± 3.7% |
| TNC Viability | 96.3 ± 1.4% | |
Source: Data on file 223-REP-048957
Quickly and easily remove platelets from leukapheresis products while recovering TNCs and maintaining cell viability.
| Measure | Result | |
|---|---|---|
| Collections (5L) |
Fenwal Amicus | n=6 |
| Spectra Optia | n=8 | |
| Source | Volume | 90.8 ± 10.2 ml |
| TNC | 4.7 ± 1.8 x 109 | |
| Final Product |
TNC Recovery | 98.6% |
| TNC Viability | 97.5% | |
| Target Final Volume | 95 mL | |
| Actual Final Volume | 95.3 ± 0.6 mL | |
| Processing Time | Average | 11:01 min |
| Maximum | 11:29 min | |
Source: Data on file 223-REP-048957
Pre/Post Lovo Wash Platelet Count & Depletion
Source: Data on file 223-REP-048957
Quickly and easily wash and concentrate up to 22L of cultured cells in one automated and functionally closed system.
Study objective
Goals
| Cell Type | Lovo Fresenius Kabi |
CS5+ Haemonetics |
Manual |
|---|---|---|---|
| Recovery (%) | 93 ± 4 | 87 ± 3 | 91 ± 4 |
| Processing Time (min) | 30 ± 1 | 25 ± 4 | 61 ± 11 |
| Washout Efficiency (%) | 99.5 | 99.9 | 99.8 |
| Final Volume (mL) | 150 ± 1 | 153 ± 3 | 151 ± 6 |
| Cellular CQAs1 | comparable | ||
| Automated | ✓ | ± | x |
| Functionally Closed | ✓ | ± | x |
1 Critical Quality Attributes (CQAs) Measured: viability assessment, phenotype, cell functionality, ancillary materials.
Source: Presented by Ian Gaudet, PhD. Senior Engineer, PCT. IBC Commercialization of Cell, Gene, and Immunotherapies, San Diego, CA. 2014.
Wash cryopreserved products and resuspend cells in your preferred buffer or culture media.
| Measure | Lovo 2.0 (three-cycle) |
|---|---|
| Number of Runs | 6 |
| PCV% | 8.4% (6.9 - 11.4) |
| Viable CD34+ Cell Recovery | 84% (61 - 93) |
| CD34+ Cell Viability | 92% (81 - 94) |
| DMSO Elimination | 97% (97 - 98) |
| Total Processing Time | 62 min |
† Data is expressed as median and (IQR)
Source: Mfarrej B., Bouchet G., Couquiaud J., Regimbaud L., Binninger S., Mercier M., … Calmels B. (2017) Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017.
3-Cycle Wash1
Post Thaw Recovery
Source: Mfarrej B., Bouchet G., Couquiaud J., Regimbaud L., Binninger S., Mercier M., … Calmels B. (2017) Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, 2017.
Stay Informed.
Sign up below to receive the latest Lovo news and updates.
See Us In Action.
Come see what Lovo’s all about. We’ll walk you through the features and arrange a demo.
European Bone Marrow Transplant (EBMT)
March 22 - 25, 2020
RAI, Madrid, Spain
Innate Killer Summit
March 24 – 26, 2020
San Diego, California
The LOVO Cell Processing system is for laboratory use only. Unless the user has obtained advance clearance or approval from the appropriate regulatory agency, cells processed on this system are not intended for diagnostic purposes, direct transfusion, or for use in the production of therapeutic products or vaccines for clinical use. For applications requiring regulatory clearance or approval, users may obtain the required LOVO information from Fresenius Kabi to support their submission.